BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
10 May 2016

Abstract

Patients should be tested for hepatitis B virus before starting treatment with BCR-ABL tyrosine kinase inhibitors.